Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 6/20 | 0.55 |
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.40 |
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.40 |
| ▸ | ITGB3 known ✓ | P05106 | 1/20 | 0.40 |
| ▸ | ITGA2B known ✓ | P08514 | 1/20 | 0.40 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.39 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.39 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.39 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.39 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.39 |
| ▸ | DRD2 known ✓ | P14416 | 1/20 | 0.39 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.39 |
| ▸ | CHRM3 known ✓ | P20309 | 1/20 | 0.39 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.39 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.39 |
| ▸ | EDNRA known ✓ | P25101 | 1/20 | 0.39 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.39 |
| ▸ | AVPR2 known ✓ | P30518 | 1/20 | 0.39 |
| ▸ | AGTR1 known ✓ | P30556 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128980 | 0.99 | PTGS2 (0.56) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Nitric Acid SCHEMBL4138682 | 0.97 | PTGS2 (0.54) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL7130432 | 0.90 | PTGS2 (0.59) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL7845555 | 0.90 | PTGS2 (0.42) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL4134235 | 0.89 | HPGD (0.42) | PTGS2HSD17B10KDM4ELMNAMAPT | |
| SCHEMBL7851267 | 0.89 | PTGS2 (0.43) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Nitric Acid SCHEMBL28748383 | 0.87 | PTGS2 (0.42) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL4029457 | 0.83 | PTGS2 (0.61) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| SCHEMBL3651806 | 0.82 | PTGS2 (0.63) | PTGS2HSD17B10KDM4ELMNACYP1A2 | |
| Hydrochloric Acid SCHEMBL4125862 | 0.81 | PTGS2 (0.53) | PTGS2HSD17B10KDM4ELMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | claimed |
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | claimed |
| US-20040023890-A1 | Drugs for diabetes | NICOX S.A. (FR) | 2004-02-05 | — | — | US | claimed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | claimed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | claimed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| EP-1154999-B1 | NITROXYDERIVATIVES HAVING ANTIINFLAMMATORY, ANALGESIC AND ANTITHROMBOTIC ACTIVITY | NICOX SA (FR) | 2009-04-15 | — | — | EP | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| US-7378437-B2 | Use for the diabetes treatment of compounds or salts thereof, having the following general formula (I): A-(B)b0-(C)c0-NO2 wherein A contains the radical of a drug having an antiiflammatory or analgesic activity, B is a bivalen: linking | NICOX S.A. (FR) | 2008-05-27 | — | — | US | disclosed |
| EP-1339665-B1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX SA (FR) | 2007-12-19 | — | — | EP | disclosed |
| US-20030203899-A1 | Drugs for incontinence | NICOX S.A. (FR) | 2003-10-30 | — | — | US | disclosed |
| US-20030171393-A1 | Drugs for sex dysfunctions | NICOX S.A. (FR) | 2003-09-11 | — | — | US | disclosed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | disclosed |
| US-6613784-B1 | Cyclooxygenase inhibitors such as 2-acetyloxybenzoic acid 6-(nitroxymethyl)-2-methylpyridinyl ester hydrochloride, having good kinetics, solubility and efficiency; nontoxic | NICOX S.A. (FR) | 2003-09-02 | — | — | US | disclosed |
| EP-1324974-A2 | DRUGS FOR DIABETES | Nicox S.A. (FR) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002030867-A2 | DRUGS FOR DIABETES | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
| WO-2002011706-A2 | DRUGS FOR SEX DYSFUNCTIONS | NICOX S.A. (FR) | 2002-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171393-A1 | Drugs for sex dysfunctions | SRD5A1, SRD5A2, XDH | PTGS2 1140/4885PTGS1 380/4885ESR1 979/4885 |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | PTGS2 110/4885PTGS1 47/4885ESR1 218/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | PTGS2 141/4885PTGS1 55/4885ESR1 67/4885 |
| US-20040023890-A1 | Drugs for diabetes | SLC5A2, ADORA2B, UGT2B7 | PTGS2 91/4885PTGS1 113/4885ESR1 1628/4885 |
| US-20030203899-A1 | Drugs for incontinence | PDE3A, NOS1, PDE3B | PTGS2 270/4885PTGS1 70/4885ESR1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.